MENU
+Compare
MRNA
Stock ticker: NASDAQ
AS OF
Jul 3 closing price
Price
$30.49
Change
+$0.21 (+0.69%)
Capitalization
11.79B

MRNA Moderna Forecast, Technical & Fundamental Analysis

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018... Show more

Industry: #Biotechnology
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for MRNA with price predictions
Jul 03, 2025

MRNA in upward trend: 10-day moving average crossed above 50-day moving average on June 30, 2025

The 10-day moving average for MRNA crossed bullishly above the 50-day moving average on June 30, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 30, 2025. You may want to consider a long position or call options on MRNA as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MRNA just turned positive on June 26, 2025. Looking at past instances where MRNA's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .

MRNA moved above its 50-day moving average on June 24, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MRNA broke above its upper Bollinger Band on July 01, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.172) is normal, around the industry mean (16.666). P/E Ratio (0.000) is within average values for comparable stocks, (58.763). MRNA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.315). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (3.740) is also within normal values, averaging (269.614).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MRNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

MRNA is expected to report earnings to rise 17.46% to -296 cents per share on July 31

Moderna MRNA Stock Earnings Reports
Q2'25
Est.
$-2.96
Q1'25
Beat
by $0.66
Q4'24
Missed
by $0.18
Q3'24
Beat
by $1.95
Q2'24
Beat
by $0.02
The last earnings report on May 01 showed earnings per share of -251 cents, beating the estimate of -318 cents. With 6.97M shares outstanding, the current market capitalization sits at 11.79B.
A.I. Advisor
published General Information

General Information

a developer of transformative medicines for patients

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
200 Technology Square
Phone
+1 617 714-6500
Employees
5600
Web
https://www.modernatx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SVOL19.270.90
+4.90%
Simplify Volatility Premium ETF
AUDHKD5.16N/A
N/A
Australian Dollar - Hong Kong Dollar
GBPCNY9.79N/A
N/A
United Kingdom Pound - China Yuan
NZDAUD0.92-0.00
-0.07%
New Zealand Dollar - Australian Dollar
CHFUSD1.26-0.00
-0.31%
Switzerland Franc - United States Dollar

MRNA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MRNA has been loosely correlated with ARCT. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MRNA jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRNA
1D Price
Change %
MRNA100%
+0.69%
ARCT - MRNA
50%
Loosely correlated
+1.17%
BNTX - MRNA
48%
Loosely correlated
+1.61%
CRSP - MRNA
48%
Loosely correlated
+0.97%
NVAX - MRNA
45%
Loosely correlated
+0.59%
RGNX - MRNA
44%
Loosely correlated
+1.39%
More